Teriflunomide May Delay Onset of MS Symptoms in People With RIS
A recent Phase 3 trial showed people with radiologically isolated syndrome (RIS) who took Aubagio were 72 percent less likely to later develop MS symptoms.
Source: everydayhealth.com